MENU
+Compare
CRON
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$1.97
Change
+$0.03 (+1.55%)
Capitalization
1B

CRON stock forecast, quote, news & analysis

CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CRON with price predictions
Feb 18, 2025

CRON's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CRON turned positive on February 05, 2025. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 77 cases where CRON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 05, 2025. You may want to consider a long position or call options on CRON as a result. In of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for CRON crossed bullishly above the 50-day moving average on February 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

CRON moved below its 50-day moving average on February 18, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRON broke above its upper Bollinger Band on February 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRON entered a downward trend on February 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.912) is normal, around the industry mean (59.679). P/E Ratio (0.000) is within average values for comparable stocks, (89.540). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (11.481) is also within normal values, averaging (19.827).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.6B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was 78%, and the average quarterly price growth was 51%. ECGS experienced the highest price growth at 154%, while INNPF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 65%. For the same stocks of the Industry, the average monthly volume growth was 82% and the average quarterly volume growth was 249%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 69
Price Growth Rating: 62
SMR Rating: 84
Profit Risk Rating: 90
Seasonality Score: -41 (-100 ... +100)
View a ticker or compare two or three
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

pharmaceutical, medical marijuana, cannabis

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
111 Peter Street
Phone
+1 416 504-0004
Employees
447
Web
https://www.thecronosgroup.com